This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on updates on pipeline candidates, especially NTLA-2001, when Intellia (NTLA) reports second-quarter earnings.
What's in Store for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Pharma & Healthcare ETFs at a One-Year High: Here's Why
by Sanghamitra Saha
Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $345.64, marking a -1.05% move from the previous day.
Moderna (MRNA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY
by Zacks Equity Research
The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.
Time for Pharma and Healthcare ETFs?
by Sanghamitra Saha
The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $323.48 in the latest trading session, marking a +0.74% move from the prior day.
Should Direxion NASDAQ100 Equal Weighted Index Shares (QQQE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQE
Moderna (MRNA) Set to Join S&P 500 Riding on Vaccine Success
by Zacks Equity Research
Moderna's (MRNA) success with its COVID-19 vaccine, mRNA-1273, continues to drive the stock. The company crosses $100-billion in market capitalization and will join the S&P 500 soon.
Moderna (MRNA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $235.15 in the latest trading session, marking a -1.75% move from the prior day.
Moderna (MRNA) Set to Supply Argentina With COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) signs an agreement with the government of Argentina for supplying 20 million doses of its COVID-19 vaccine, mRNA-1273, or an updated booster vaccine shot, if approved.
J&J (JNJ) COVID-19 Jab Linked to New Rare Neurological Disorder
by Zacks Equity Research
FDA warns of increased risk of Guillain-Barre syndrome, a rare neurological disorder with J&J's (JNJ) COVID-19 vaccine.
Company News for Jul 13, 2021
by Zacks Equity Research
Companies In The News Are: MRNA, DIS, AVGO, JWN
Alexion (ALXN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Alexion (ALXN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AbbVie (ABBV) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Bear of the Day: Inovio Pharmaceuticals (INO)
by Madeleine Johnson
Is it too late to buy this coronavirus vaccine stock?
BioNTech (BNTX)/ Pfizer to Seek FDA Nod for COVID-19 Booster
by Zacks Equity Research
BioNTech (BNTX) and partner Pfizer plan to get authorization for COVID-19 booster vaccine shot in the United States owing the emerging Delta variant of the virus.
Moderna (MRNA) Begins Dosing in Study on mRNA Flu Vaccine
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase I/II study on its quadrivalent mRNA-based vaccine candidate, mRNA-1010, against seasonal influenza.
The Zacks Analyst Blog Highlights: Shopify, Lowe's, CVS Health, Moderna and The Bank of New York Mellon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Shopify, Lowe's, CVS Health, Moderna and The Bank of New York Mellon
Vaccine Stocks Fall as Delta Becomes Dominant Variant in US
by Kinjel Shah
Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.
Top Research Reports for Shopify, Lowe's & CVS Health
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Shopify (SHOP), Lowe's Companies (LOW), and CVS Health (CVS).
Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
3 Biotech Stocks Poised to Gain in the Second Half of 2021
by Ekta Bagri
Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.